Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• GTPases (like Ras) and kinases regulate cell fate and are implicated in cancers.
• K-Ras mutations are prevalent in pancreatic ductal adenocarcinomas (PDAC), with aberrant PI3K/AKT/mTOR pathway activity linked to PDAC.
• Effective therapeutics for pancreatic cancer remain limited.

Purpose of the Study:

• To review recent advances in developing allosteric drugs targeting Ras GTPases and the PI3K/AKT/mTOR pathway.
• To highlight the merits of allosteric inhibition for complex signaling modules in cancer treatment.

Main Methods:

• Focus on emerging insights into allosteric regulatory mechanisms.
• Exploration of fragment-based drug discovery (FBDD) for developing selective allosteric inhibitors.
• Review of pre-clinical development of allosteric inhibitors for Ras and AKT.

Main Results:

• Allosteric inhibition presents a promising strategy for targeting Ras and PI3K/AKT/mTOR pathway kinases.
• Fragment-based drug discovery facilitates the development of selective allosteric inhibitors.
• Allosteric inhibitors for Ras and AKT are advancing in pre-clinical development.

Conclusions:

• Allosteric drug development targeting Ras and PI3K/AKT/mTOR pathways offers novel therapeutic opportunities for pancreatic cancer.
• Overcoming challenges posed by complex regulatory mechanisms and conserved isoforms is achievable through allosteric approaches.
• The development of selective allosteric inhibitors is a key strategy for future cancer therapeutics.